Skip to main content
. 2021 Jun 29;106(11):e4400–e4413. doi: 10.1210/clinem/dgab478

Table 1.

Baseline patient characteristics

Patient characteristics (n = 75)
Age, y 50 (range 29-65)
Gender, n (%)
 Female 58 (77.3)
 Male 17 (22.7)
Race, n (%)
 Caucasian 58 (77.3)
 African American 12 (16.0)
 Asian 3 (4.0)
 Hispanic 2 (2.7)
Clinical measures
 Weight mean, lb (SD) 180 (40.2)
Cause of hypothyroidism, n (%)
 Autoimmune, Hashimoto 46 (61.3)
 Post-radioiodine, Graves’ disease 4 (5.3)
 Postthyroidectomy 16 (21.3)
 Idiopathic 9 (12.1)
Biochemical measures, mean (SD)
 Total cholesterol (<200 mg/dL) 199 (39.8)
 LDL cholesterol (<100 mg/dL) 128 (36.0)
 HDL cholesterol (>60 mg/dL) 61.0 (18.6)
 Triglyceride (<150 mg/dL) 106 (60.7)
 Total T3 (60-181 ng/dL) 109 (27.3)
 T3 resin uptake (22-35%) 28.0 (3.53)
 T3 reverse (11-32 ng/dL) 19.9 (6.81)
 TSH (0.27-4.20 uIU/mL) 1.77 (1.10)
 Total T4 (4.5-12 μg/dL) 8.21 (2.22)
 Free T4 (0.89-1.76 ng/dL) 1.41 (0.37)
 Free T4 direct dialysis (0.8-2.7 ng/dL) 1.29 (0.38)
 SHBG (17-124 nmol/L) 71.0 (51.7)
 Leptin (<60 ng/mL for BMI < 30) 20.2 (14.9)
Prestudy medications, mean (SD), (n)
 LT4 dosage (mcg) 112.5 (28.7), (n = 64)
 DTE dosage (mg) 71.2 (10.9), (n = 8)
 LT4 + LT3 dosage (mcg) 97.3 (16.2) + 5 (0), (n = 3)

Abbreviations: DTE, desiccated thyroid extract; HDL, high density lipoprotein; LDL, low density lipoprotein; LT3, liothyronine; LT4, levothyroxine.